

# ANGIOJET<sup>®</sup> ULTRA Thrombectomy System **ENHANCING YOUR OPTIONS** FOR RESTORING FLOW

# When you need the versatility and power to restore flow

Refined from experience in over 700,000 cases worldwide, today's AngioJet System offers the reliable and predictable performance<sup>1</sup> needed to treat the widest range of thrombotic occlusions – including clots from vessels as small as 1.5mm to the largest clot burdens in iliofemoral veins.

# A powerful, yet controlled, mechanism of action

For Large and Small Thrombus Burden

### Some of the potential benefits of using **AngioJet Thrombectomy include:**

- Rapid removal of thrombus<sup>1</sup>
- Quick restoration of blood flow<sup>2,3</sup>
- Resolution of symptoms<sup>2,3</sup>

With single-package disposables and an intuitive console, the AngioJet Thrombectomy System simplifies setup and user controlled thrombectomy power

## **ADVANCED, USER-FRIENDLY CONSOLE**

- Control system automates set-up and monitors operation
- Step-by-step interface for procedural efficiency
- Automated system self-configures to each catheter
- Compact, highly mobile console





Saline jets travel backward within the catheter at high speed creating a powerful vacuum effect



Cross-Stream<sup>™</sup> flow is specially designed to optimize thrombus removal



Thrombus is drawn into the catheter where it is fragmented and evacuated from the body



## **Power Pulse<sup>™</sup> Lytic Delivery**

Available on Solent<sup>™</sup> family of peripheral catheters, Power Pulse<sup>™</sup> Delivery enables lytic delivery for thrombus treatment

Delivers medication directly into the clot, where it's most effective, saturating and softening tough thrombus to facilitate removal

# **Peripheral Venous Thrombus**

Post Thrombotic Syndrome (PTS) is a chronic, debilitating complication of DVT occurring in 20-50% of patients following a proximal DVT.<sup>4</sup>

The AngioJet System provides the power and flexibility to remove thrombus and restore flow in even challenging DVT cases.

#### **Recent PEARL Registry data showed:**<sup>1</sup>

- AngioJet Thrombectomy removed a mean of 95% thrombus burden in veins – with 76% of DVT treatments completed in less than 24 hours and 81% of patients remaining free of rethrombus at 12 months
- 86% of cases utilized Power Pulse and/or Rapid Lysis approach (N=371 patients)
- Less lytic and shorter procedure times using either Power Pulse or Power Pulse plus CDT than with CDT alone with AngioJet
- 87% of AngioJet venous cases were completed in 2 or less sessions

AngioJet Percutaneous Mechanical Thrombectomy for DVT can result in less treatment time and cost efficiencies compared to traditional CDT.<sup>2</sup>



The Solent Omni and Proxi catheters were designed with a stronger thrombectomy power for clearing larger thrombus burden than other AngioJet catheter models. Power Pulse Delivery can infuse lytic into the clot. Contrast injection capability and guidewire swappability increase treatment efficiencies.

Pharmacomechanical treatment of left iliac DVT





Pre-procedure venogram Pre treatment image following left popliteal stick

**Power Pulse Delivery** Post Power Pulse Delivery with AngioJet Solent Proxi; 10 mg tPA in 500ml bag, 30 minute dwell time

Dr. Ravi Rajani, Vascular Surgeon Grady Hospital, Atlanta, Georgia Procedure Date: October 30, 2013

#### Acute DVT left lower extremity swelling



Baseline 48-year-old woman with a history of metastatic cervical cancer with new left lower swelling.

**Final Result** 

Reginald Baker, MD Baptist Cardiac and Vascular Institute Miami, Florida Procedure Date: November 18, 2011



Treatment with AngioJet Solent Omni Thrombectomy catheter. No Power Pulse Delivery used. Final venogram after PTA.

Post-AngioJet Throbectomy 4 passes with Solent Proxi catheter followed by PTA



**Final Result** Post PTA of common Iliac and the external Iliac

#### **Thrombectomy in May-Thurner Syndrome DVT**



1 Pass AngioJet Solent **Proxi Catheter** Distal Iliac and Common Femoral

Post Power Pulse Delivery and AngioJet Thrombectomy 30 minute dwell time of lytics and 3 minute 10 seconds of AngioJet Thrombectomy

Dr. Ramana Yedavalli Silver Cross Hospital New Lenox, IL Procedure Date: December 12, 2012

# **Peripheral Arterial Thrombus**

Acute Limb Ischemia (ALI) remains a life-threatening condition with 9% and 15% in-hospital and 30-day mortality rates, respectively; and 15% and 25% amputation rates at discharge and 30 days.<sup>5,6</sup>

AngioJet Thrombectomy removes clot burden from arterial vessels as small as 1.5 mm restoring flow, and resolving symptoms while exposing the culprit lesion, facilitating treatment.

## **Recent PEARL Registry data showed:**<sup>1</sup>

- Immediate improvement in 93% of arterial vessels treated
- 90% limb salvage rate for patients presenting with threatened limbs at baseline (Rutherford scoring)



Solent family catheters

# **AV Access Conduits**

Thrombus narrowing or restricting flow within AV access fistulas and grafts can prevent a patient from undergoing life supportive dialysis treatment.

Used for thrombectomy of both synthetic grafts and natural fistulae, the AngioJet System utilizes powerful Cross-Stream technology to remove thrombotic materials from the dialysis access conduit with minimal vessel wall trauma, potentially decreasing the risk for future thrombotic events.

Catheters with AV access indication include: AVX, Solent Proxi and Solent Omni

**Recent PEARL Registry data showed:**<sup>1</sup>

- Patency and functionality rate of 78% at 3 months compared to KDOQI guidelines target of 40%
- Procedural success reported in 125/135 (93%)
- 3 month follow up completed in 112/130 (86%); Patency maintained in 76/112 (68%)

## **CLI with Right Foot Ulcer Thrombectomy**



Arteriogram of Posterior and Anterior Tibial post CDT

PT and AT remained occluded following overnight CDT infusion of lytic.



#### Pharmacomechanical thrombecomty with **AngioJet Solent Dista**

AngioJet Solent Dista Catheter used in Power Pulse mode in both AT and PT. 30 min dwell in AT and 45 min dwell in PT. Followed by Solent Dista Catheter used in thrombectomy mode.

Thrombectomy of left brachial artery-axillary vein graft



Pre-procedure AngioJet catheter positioned in thrombosed AV graft.







#### Post Procedure Arteriogram

Image following ballooning of small focal lesion in PT.

## **Pulmonary Embolism**

#### Speed is important!

Pulmonary embolism (PE) can be a life-threatening emergency and requires fast diagnosis and rapid haemodynamic stabilization.

> Mortality of massive pulmonary embolism remains exceedingly high despite thrombolytic therapy. Anticoagulant and thrombolytic therapies are a mainstay in the management of acute pulmonary embolism (PE), especially when hemodynamic compromise is present.

However, systemic drugs cannot achieve timely and effective treatment of acute PE in all patients. In such a setting, mechanical removal of thrombus from the pulmonary circulation holds the promise of significant clinical benefits.

> The most important feature of mechanical thrombectomy for massive PE is the immediate improvement of the cardiac output, PO2, and clinical situation, overcoming the first critical hours after massive PE.<sup>7</sup>

European Society of Cardiology guidelines identify mechanical thrombectomy as "an alternative to thrombolysis when there are absolute contraindications, as an adjunctive therapy when thrombolysis has failed to improve haemodynamics or as an alternative to surgery if immediate access to cardiopulmonary bypass is unavailable..."<sup>8</sup>



The AngioJet PE Thrombectomy Set is intended for use with the AngioJet System for removal of thrombus from main pulmonary and lobal arteries  $\ge 6$ mm.<sup>9</sup>

AngioJet Thrombectomy has been proposed in several publications as a treatment option for patients with massive and submassive pulmonary embolism, with the potential of providing rapid and significant haemodynamic improvement with encouraging results at both early and long-term follow-up.<sup>10, 11, 12, 13</sup>

"Substantial improvement in pulmonary blood flow may result from what appears to be only modest angiographic change." In fact, haemodynamic improvement may be a more indicative clinical parameter.<sup>14</sup>



## **Pulmonary Embolism**

**Case Studies** 

#### **Thrombectomy of High Risk Pulmonary Embolism**



**Pre Treatment** Patient with active GI bleeding precluding the use of lytic. Main pulmonary artery angiography (more selective to the right) performed with an angulated 6 F (2 mm) pigtail catheter, showing the presence of a large thrombus within the right and left pulmonary arteries and respective lobar branches.



#### Thrombectomy of Left Pulmonary Artery



#### Baseline pulmonary angiography Left pulmonary angiography performed with an angulated 6 F (2 mm) pigtail catheter, demonstrating the presence of thrombus within the left pulmonary artery and the upper, middle and lower lobar branches.

**Baseline pulmonary** 

angiography performed

6 F (2 mm) pigtail catheter,

demonstrating the presence

of a large thrombus within

the right pulmonary artery

and the upper, middle and lower lobar branches.

angiography

Right pulmonary

with an angulated

Massimo Margheri, Vecchio Sabine, Cardiology Department, Ravenna, Italy

#### **Thrombectomy of Right Pulmonary Artery**



Massimo Margheri, Vecchio Sabine, Cardiology Department, Ravenna, Italy



AngioJet<sup>®</sup> Thrombectomy Rheolytic thrombectomy performed with AngioJet® PE catheter through a 0.035" (0.089 mm) hydrophilic guide wire, starting in the left pulmonary artery and inferior lobar branch. Procedure was repeated in the right pulmonary artery and corresponding lobar branches. Procedure was terminated because of bradyarrhythmia. Furthermore, total activation time was near the recommended limit (4 minutes).



#### AngioJet® Thrombectomy Rheolytic thrombectomy performed with the AngioJet® PE catheter through an 8 F (2.67 mm) multipurpose guiding catheter and a 0.035" (0.089 mm) hydrophylic guide wire.

# 0

#### AngioJet® Thrombectomy

Rheolytic thrombectomy performed with the AngioJet® PE catheter through an 8 F (2.67 mm) multipurpose guiding catheter and a 0.035" (0.089 mm) hydrophylic guide wire, in the middle and lower lobar branches.



#### **Post Thrombectomy** Despite large volume of thrombus removed, final angiogram shows only a mild improvement of obstruction. However, the treatment goal is to simply restore flow and not remove all thrombus since even this modest angiographic result was accompanied with significant hemodynamic and gas exchange recovery.



**Final pulmonary angiography** Left pulmonary angiography performed after rheolytic thrombectomy showing the improvement of the obstruction and perfusion index.



**Fina I pulmonary angiography** Right pulmonary angiography performed after rheolytic thrombectomy showing the improvement of the obstruction and perfusion indexes.

## **Treat the Full Range of Thrombus**

Model	Catalog Number	Platform	Minimum Vessel Diameter	Catheter Length	Guide Wire	Power Pulse™ Delivery	Contrast Injection Port	Guidewire Swappability
Solent <sup>™</sup> Dista	111303-003	OTW	1.5 mm	145 cm	0.014″ 0.035 mm	Yes		
Solent <sup>™</sup> Omni	109681-004	OTW	3 mm	120 cm	0.035″ 0.089 mm	Yes	Yes	Yes
Solent <sup>™</sup> Proxi	109676-004	OTW	3 mm	90 cm	0.035″ 0.089 mm	Yes	Yes	Yes
AVX™	105039-003	OTW	3 mm	50 cm	0.035″ 0.089 mm		Yes	
PE	107171-003	отw	6 mm	120 cm	0.035″ 0.089 mm	Yes		
AngioJet <sup>™</sup> Console	105650							
Power Pulse <sup>™</sup> Delivery Kit	104834-0031	Delivers medication directly into the clot, where it's most effective, saturating and softening tough thrombus to facilitate removal						

1 The PEARL Registry: Endovascular Management of Deep Vein Thrombosis with Rheolytic Thrombectomy: Final Report of the Prospective Multicenter PEARL Her Legisla, Englisher Holytic Thrombectomy with a Variety of Catheter Lengths) Registry. Mark J. Garcia, MD, MS; Robert Lookstein, MD; Rahul Malhotra, MD; Ali Amin, MD, RVT; Lawrence R. Blitz, MD; Daniel A. Leung, MD; Eugene J. Simoni, MD; Peter A. Soukas, MD

2 Lin, PL, et al. Catheter-direct thrombolysis versus pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis The American Journal of Surgery 192 (2006):782–788

3 Hager, E et al. Anatomic and functional outcomes of pharmacomechanical and catheter-directed thrombolysis of iliofemoral deep venous thrombosis. J Vasc Surg Venous and Lym Dis 2014;2:246-52.

4 Kahn SR. The post-thrombotic syndrome. Hematology Am Soc Hematol Educ Program 2010; 2010:216–220.

5 Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators N Engl J Med 1998;338:1105–1111.

- 6 Dormandy J, Heeck L, Vig S. Acute limb schemia. Semin Vasc Surg 1999;12:148-153.

7 Reekers JA1, Baarslag HJ, Koolen MG, Van Delden O, van Beek EJ. Mechanical thrombectomy for early treatment of massive pulmonary embolism. Cardiovasc Intervent Radiol. 2003 May-Jun;26(3):246-50.

8 Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P et al. Guidelines on the diagnosis and management of acute pulmonary embolism. The task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). European Heart Journal, 2008;29:2276–2315. 9 AngioJet PE Thrombectomy Set Instructions for Use

10 Iskander A, Nayak A, Chauhan MS. Submassive pulmonary embolism and paradoxical embolic stroke treated with percutaneous rheolytic thrombectomy and closure of the patent foramen ovale. Catheter Cardiovasc Interv 2005;64(3):356–360.

11 Siablis D, Karnabatidis D, Katsanos K, Kagadis GC, Zabakis P, Hahalis G. AngioJet rheolytic thrombectomy versus local intrapulmonary thrombolysis in massive pulmonary embolism: A retrospective data analysis. Journal of Endovascular Therapy 2005;12(2):206-214.

12 Margheri M. Percutaneous rheolytic thrombectomy with AngioJet for pulmonary embolism: methods and results in the experience of a high-volume center. Italian Journal of Cardiology 2008;9(5):355-363

13 Arzamendi D, Bilodeau L, Ibrahim R, Noble S, Gallo R, Lavoie-L'Allier P et al. Role of rheolytic thrombectomy in massive pulmonary embolism with contraindication to systemic thrombolytic therapy. EuroIntervention 2009;5:716-721

14 Jaff M, McMurty S, Archer S, Cushman M, Goldenberg N, Goldhaber S et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension. A scientific statement from the American Heart Association. Circulation 2011;123:1788-1830. Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary.

> Boston SCIENTINC

Advancing science for life™

www.bostonscientific.eu

© 2024 Boston Scientific Corporation or its affiliates. All rights reserved. DINPER4665EA €€2797

#### Angiolet, AVX, Power Pulse, and Solent are registered or unregistered trademarks of Boston Scientific Corporation or its affiliates.

All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

Indications, operating specifications and availability may vary by country. Check with local product representation and country-specific Information For Use for your country. This material is not approved for use or distribution in France.

PI-323002-AA JUN 2015